The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Drug-induced psoriasis: clinical perspectives
Open accessAbstract
Exposure to certain drugs can elicit an induction or exacerbation of psoriasis. Although well-conducted systematic studies on drug-related psoriasis are mostly lacking, traditionally strong associations have been documented for beta-blockers, lithium, antimalarial drugs such as (hydroxy)chloroquine, interferons, imiquimod, and terbinafine. More recently, new associations have been reported for monoclonal antibody- and small-molecule-based targeted therapies used for oncological and immunological indications, such as tumor necrosis factor-alpha antagonists and anti-programmed cell death protein 1 immune checkpoint inhibitors. Recognizing potential drug-related psoriasis is of clinical relevance to allow an optimal management of psoriasis. However, in clinical practice, identifying medication-related exacerbations and induction of psoriasis can be challenging. The clinical and histopathological features of drug-provoked psoriasis may differ little from that of "classical" nondrug-related forms of psoriasis. In addition, the latency period between start of the medication and onset of psoriasis can be significantly long for some drugs. Assessment of the Naranjo adverse drug reaction probability scale could be used as a practical tool to better differentiate drug-related psoriasis. The first step in the management of drug-related psoriasis is cessation and replacement of the offending drug when deemed clinically possible. However, the induced psoriasis skin lesions may persist after treatment withdrawal. Additional skin-directed treatment options for drug-related psoriasis follows the conventional psoriasis treatment guidelines and includes topical steroids and vitamin D analogs, ultraviolet phototherapy, systemic treatments, such as acitretin, methotrexate, and fumaric acid esters, and biological treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914 · cited 1×
“A tool to help to better discern potential causal drug relations is the Naranjo adverse drug reaction probability scale.(13,16) The scale consists of 10 questions, the scoring of which results into four categories: definite, probable, possible, and doubtful (Table 2).”
MethodPattern Analysis of Drug-Induced Skin Diseases
Justiniano, H., Berlingeri-Ramos, A. C., & Sánchez, J. L. (2008) · The American Journal of Dermatopathology · doi:10.1097/dad.0b013e3181722ef4 · Cited by 86
Cited by
Risk Factors for the Development of Psoriasis
Kamiya, K., Kishimoto, M., Sugai, J., Komine, M., & Ohtsuki, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184347 · Cited by 640
Metadata
- Authors
- Balak, D., & Hajdarbegovic, E.
- Venue
- Psoriasis: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-12
- Volume
- Volume 7
- Pages
- 87-94
- ISSN
- 2230-326X (ISSN-L)
- OpenAlex
- W2772985695
- Cited by
- 173
- References
- 2
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug-induced psoriasis: clinical perspectives. https://app.cochat.ai/papers/10.2147/ptt.s126727
- The paper
- Balak, D., & Hajdarbegovic, E. (2017). Drug-induced psoriasis: clinical perspectives. Psoriasis: Targets and Therapy. https://doi.org/10.2147/ptt.s126727
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.